UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000002396
Receipt number R000002888
Scientific Title Feasibility trial of neoadjuvant chemotherapy with docetaxel,cisplatin and fluorouracil for clinical stage II/III esophageal carcinoma.
Date of disclosure of the study information 2009/09/01
Last modified on 2011/08/30 20:52:56

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Feasibility trial of neoadjuvant chemotherapy with docetaxel,cisplatin and fluorouracil for clinical stage II/III esophageal carcinoma.

Acronym

neoadjuvant DCF for esophageal carcinoma

Scientific Title

Feasibility trial of neoadjuvant chemotherapy with docetaxel,cisplatin and fluorouracil for clinical stage II/III esophageal carcinoma.

Scientific Title:Acronym

neoadjuvant DCF for esophageal carcinoma

Region

Japan


Condition

Condition

esophageal neoplasm

Classification by specialty

Gastroenterology Gastrointestinal surgery

Classification by malignancy

Malignancy

Genomic information

NO


Objectives

Narrative objectives1

to evaluate the safety and efficacy of neoadjuvant chemotherapy with docetaxel,cisplatin and fluorouracil in patients with clinical stage II/III esophageal carcinoma.

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1

Exploratory

Trial characteristics_2


Developmental phase

Phase II


Assessment

Primary outcomes

The rate of treatment completion

Key secondary outcomes

Overall survival
Progression free survival
Resectability rate
Adverse event
Response rate


Base

Study type

Interventional


Study design

Basic design

expanded access

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Historical

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

2

Purpose of intervention

Treatment

Type of intervention

Medicine Maneuver

Interventions/Control_1

initial cohort n=30
aged 70 or younger

docetaxel 70 mg/m2/day day1 iv
cisplatin 70 mg/m2/day day1 iv
5-fluorouracil 750 mg/m2/day day1-5 civ
q3w , 3 cycle
Esophagectomy with D2 (or more) lymph node desection

Interventions/Control_2

expanding cohort n=10
aged 75 or younger

docetaxel 75 mg/m2/day day1 iv
cisplatin 75 mg/m2/day day1 iv
5-fluorouracil 750 mg/m2/day day1-5 civ
q3w , 3 cycle
Esophagectomy with D2 (or more) lymph node desection

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

75 years-old >=

Gender

Male and Female

Key inclusion criteria

1) Histologically proven squamous cell carcinoma or adenosquamous cell carcinoma of the esophagus
2) Primary lesion are located within the thoracic esophagus (Te)
3) Clinical stage II or III without T4
4) Aged 20 to 75 years old
(expanding cohort ; aged 75 or younger)
5) ECOG PS of 0 or 1
6) no need for measurable lesion
7) no previous treatment of esophageal cancer
8) no previous chemotherapy or radiotherapy against any other malignancies
9) no palsy of recurrent nerve
10) adequate organ functions
11) curative resection for esophageal carcinoma
12) written informed consent

Key exclusion criteria

1) Simultaneous or metachronous (within 5 years) double cancers , with the exception of intramucosal tumor curable with local therapy
2) Pregnant or lactating women or women of childbearing potential
3) Psychosis
4) Patients requiring systemic steroids medication
5) HBs antigen positive
6) Uncontrollable diabetes millutus
7) History of myocardial infarction or unstable angina pectoris or interstitial pneumonia or fibroid lung or severe emphysema
8) Active bacterial or fungous infection

Target sample size

40


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Makoto Tahara, MD, PhD

Organization

National Cancer Center Hospital East

Division name

Division of Digestive Endoscopy and GI Oncology

Zip code


Address

6-5-1 Kashiwanoha, Kashiwa, Chiba, 277-8577, JAPAN

TEL

04-7133-1111

Email



Public contact

Name of contact person

1st name
Middle name
Last name Hiroki Hara, MD

Organization

Saitama Cancer Center

Division name

Department of Gastroenterology

Zip code


Address

818 Komuro, Ina, Saitama 362-0806, Japan

TEL

048-722-1111

Homepage URL


Email

hirhara@cancer-c.pref.saitama.jp


Sponsor or person

Institute

Saitama Cancer Center

Institute

Department

Personal name



Funding Source

Organization

Foundation for promotion of cancer research in Japan

Organization

Division

Category of Funding Organization

Non profit foundation

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

国立がん研究センター東病院(千葉県)
国立がん研究センター中央病院(東京都)
栃木県立がんセンター(栃木県)
自治医科大学(栃木県)
埼玉県立がんセンター(埼玉県)
大阪医科大学(大阪府)


Other administrative information

Date of disclosure of the study information

2009 Year 09 Month 01 Day


Related information

URL releasing protocol


Publication of results

Partially published


Result

URL related to results and publications

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=102&abstractID=79240

Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

No longer recruiting

Date of protocol fixation

2009 Year 07 Month 01 Day

Date of IRB


Anticipated trial start date

2009 Year 07 Month 01 Day

Last follow-up date

2011 Year 11 Month 01 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2009 Year 08 Month 28 Day

Last modified on

2011 Year 08 Month 30 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000002888


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name